-
Notice on Public Solicitation of Opinions on the "Catalogue of Reference Preparations of Chemical Generic Drugs (Fiftieth Batch)" (Draft for Solicitation of Comments)
Time of Update: 2021-10-19
According to the "Announcement on the Selection and Determination Procedures for the Publication of Chemical Generic Drug Reference Preparations" issued by the National Bureau on March 28, 2019 (No.
docx 2 Application Form for Objection to Chemical Generic Drug Reference Preparation.
-
Experts recommend immunization of the new crown vaccine booster for immune-compromised people
Time of Update: 2021-10-19
At present, the new crown vaccines that have been certified for emergency use by WHO include: vaccines jointly developed by Pfizer Pharmaceuticals Co.
-
Genting Xinyao and AbCellera announce multi-target cooperation to advance the research and development of new antibody drugs
Time of Update: 2021-10-11
HK) and AbCellera (Nasdaq: ABCL) announced today that they have reached a multi-year cooperation and Licensing agreement to conduct research on up to 10 targets selected by Genting Shinyao and discover therapeutic antibodies .
-
Gansu Dingxi Traditional Chinese Medicine Introduces "National Standard" Education Brand: Inheriting and Innovating the Development of Traditional Chinese Medicine
Time of Update: 2021-10-11
The inaugural meeting of the Gansu Provincial Liaison Station of the National Alliance for Standardization and Quality Evaluation of Chinese Medicinal Materials was held on the 27th in Longxi County,
-
Temozolomide for injection, a subsidiary of Xintian Pharmaceutical's shareholding company, obtained drug registration approval
Time of Update: 2021-10-11
Temozolomide is a new type of alkylating agent anti-tumor drug, which is mainly used for the treatment of glioma.
As a cytotoxic alkylating agent, temozolomide can directly damage the DNA of tumor cells, and rapidly and spontaneously transform into active substances in the physiological environment of the body.
-
Nuggets: Is the product that failed the reference preparation a point of opportunity?
Time of Update: 2021-10-11
, but the same generic name product can still be imitated and declared for consistency evaluation if the reference preparation has been disclosed before, for example, oxaliplatin injection, 43 batches The reason for the failure is that "after the review of the consistency evaluation expert committee, the proposed reference preparation is a generic drug marketed in the United States, does not have the status of a reference preparation, and the review failed.
-
Genetron Health and Yingpai Pharmaceutical Co., Ltd. reached a cooperation to jointly promote the development of synthetic lethal pipeline
Time of Update: 2021-10-11
Beijing, September 27, 2021/PRNewswire/ - Today, Genetron Health (Nasdaq: GTH) and Impair Pharmaceutical announced that the two parties have reached a project cooperation in the process of drug research and subsequent development, in order to jointly promote the Research on synthetic lethal inhibitors of new targets and development of accompanying diagnostic products .
-
Hebo Pharmaceutical Bartolizumab completes the first patient's administration for the Phase III trial of systemic myasthenia gravis
Time of Update: 2021-10-11
HK) recently announced that its fully human anti-FcRn antibody Bartoli The clinical trial of monoclonal antibody (HBM9161) for systemic myasthenia gravis (gMG) has completed the first administration of the first subject of the registration phase III trial .
-
Dulaglutide biosimilar drug: Boan Biotech gets clinical approval
Time of Update: 2021-10-11
It has been approved for marketing in 2014 and has become Currently, the world's highest-selling GLP-1 receptor agonist hypoglycemic drug, with sales of up to 5.
Only two biosimilar drugs have started clinical trials.
-
WuXi Giant Nuo announces approval of JWCAR129 clinical trial application
Time of Update: 2021-10-11
Shanghai, September 27, 2021/PRNewswire/ - WuXi Giant Nuo (HKEx code: 2126), an innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products, today announced its The application for a clinical trial targeting BCMA chimeric antigen receptor (CAR) T cell JWCAR129 for the treatment of relapsed/refractory multiple myeloma has been approved by the National Medical Products Administration (NMPA) of China .
-
Tengshengbo Pharmaceutical Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
Time of Update: 2021-10-11
HK, hereinafter referred to as "Tengsheng Biopharma" or "Company"), a multinational company dedicated to the development of innovative treatments for patients' unmet needs and major public health diseases, today announced the appointment of Coy Stout as senior vice president and head of U.
-
Guangdong Provincial Food and Drug Administration issued the second phase of drug random inspection notice, a total of 9 batches of drugs were unqualified
Time of Update: 2021-10-11
After verification and confirmation, the sampling information of this issue is announced as follows: 1349 batches of 654 varieties have been inspected to meet the requirements of drug standards .
-
Kangfang Biology initiates global phase 2 clinical treatment of atopic dermatitis with IL-4Rα monoclonal antibody
Time of Update: 2021-10-11
Text|Pharmaceutical Mission HillsOn September 27, the global phase 2 clinical trial of IL-4Rα monoclonal antibody injection (AK120), an innovative drug candidate independently developed by Kangfang Bio for the treatment of moderate to severe atopic dermatitis (AD), has been launched and won the United States FDA's consent .
-
The results of the second phase of Hubei Province drug quality sampling inspection in 2021 announced 13 batches that did not meet the standards
Time of Update: 2021-10-11
The Hubei Provincial Drug Administration has instructed relevant departments to take necessary control measures such as seizures, seizures, suspension of sales, recalls and other necessary control measures for drugs that do not meet the requirements of the inspection, and to investigate and deal with the production enterprises and sampled units in accordance with relevant laws and regulations, and the treatment results and related Report the situation to the provincial bureau in time .
-
Head-to-head K drug Hengrui enters the game
Time of Update: 2021-10-11
Clinical registration of carrelizumab + famitinib combination therapy(From Insight database)Among them, the indications for cervical cancer have progressed the fastest, and phase III clinical trials have been launched in June 2021 .
-
Personnel changes in many pharmaceutical companies! Involving the chairman, vice president, deputy general manager...
Time of Update: 2021-10-11
According to incomplete statistics from Cyber Blue, a total of 7 senior executives of pharmaceutical companies resigned in September, involving positions including chairman, vice president, and deputy general manager .
-
AstraZeneca Olapali successfully first-line treatment of prostate cancer in Phase III clinical trial
Time of Update: 2021-10-11
On September 24, AstraZeneca announced that olaparza (Lynparza) combined with abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) phase III clinical PROpel study reached rPFS (radiological progress in the interim analysis) Survival) the primary endpoint, showing a statistically significant and clinically significant improvement, regardless of the patient's homologous recombination repair (HRR) mutation status .
-
Another foreign company has replaced the general manager of Greater China!
Time of Update: 2021-10-11
Hu Hai from Johnson & Johnson Orthopedics joined Xerox and will serve as The position of general manager of Xerox Greater China, Base is in Shanghai, reporting directly to MyraEskes, President of Xerox Asia Pacific .
-
Jointown Co., Ltd. cooperates with a company under Gerry Pharmaceuticals
Time of Update: 2021-10-11
The adaptability of channels and products is the key that innovative pharmaceutical companies need to consider when choosing partners01 Responsible for promoting new drugs for liver disease01 Responsible for promoting new drugs for liver diseaseOn September 25th, Jointown signed a cooperation agreement with Gele Biotech (Hangzhou) Co.
-
The "2020-2021 Chinese Family Standing Medicine Listed Brands" campaign is underway
Time of Update: 2021-10-11
Shanghai, September 22, 2021/PRNewswire/ - Starting in June of this year, in order to enhance the brand power of outstanding pharmaceutical companies and products, we will provide every Chinese family with a scientific and practical family-prepared medicine guide, "2020 -In 2021, China's household standing medicines will be listed on the "Brands" campaign, which is currently under application .
